Printer Friendly

ANERGEN REPORTS FISCAL 1992 RESULTS

 REDWOOD CITY, Calif., Feb. 25 /PRNewswire/ -- Anergen Inc. (NASDAQ: ANRG) today reported a net loss of $5,553,000, or $.99 per share, for the year ended Dec. 31, 1992, as compared to a loss of $3,893,000, or $.96 per share, for the year ended Dec. 31, 1991. The company's loss for the quarter ended Dec. 31, 1992 was $1,733,000, or $.31 per share, as compared to a loss of $1,095,000, or $.21 per share, in the quarter ended Dec. 31, 1991.
 The company's Chief Executive Officer, John W. Fara, Ph.D., said "Our results reflect increased activities in research programs and the costs associated with the completion of our pilot scale manufacturing facility." Anergen completed the construction and validation of its pilot manufacturing facility giving it the capability to manufacture its products in compliance with Good Manufacturing Practices regulations. In addition, the company stated that it has arranged financing for the $1.4 million cost of the facility through Meier Mitchell & Co. of San Francisco.
 Anergen, headquartered in Redwood City, is developing proprietary therapies for the treatment of autoimmune diseases using biopharmaceutical compounds that are designed to inactivate the specific T cells in the immune system responsible for such diseases.
 ANERGEN INC.
 Selected Financial Data
 (In thousands except per share data)
 Year ended
 Dec. 31,
 1992 1991
 Operations Data
 Expenses:
 Research and development $4,525 $2,696
 General and administrative 1,494 1,218
 Interest, net (466) (21)
 Net loss $5,553 $3,893
 Net loss per share $0.99 $0.96
 Shares used in calculating
 per share data 5,599 4,059
 Balance sheet data Dec. 31, Dec. 31,
 1992 1991
 Cash and short-term
 investments $8,918 $13,655
 Working capital 7,234 12,785
 Total assets 10,724 14,350
 Total liabilities 2,867 1,162
 Shareholders' equity 7,857 13,188
 -0- 2/25/93
 /CONTACT: Joan Shields, investor relations, or John Varian, CFO, of Anergen, 415-361-8901; or Mark J. Brand of Pondel Parsons & Wilkinson, 310-207-9300, for Anergen/
 (ANRG)


CO: Anergen Inc. ST: California IN: MTC SU: ERN

JB-JL -- LA004 -- 0254 02/25/93 09:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 25, 1993
Words:357
Previous Article:LANCASTER COLONY DECLARES CASH DIVIDEND; SETS 4-FOR-3 STOCK SPLIT
Next Article:WINTHROP RESOURCES REPORTS RECORD EARNINGS FOR YEAR, FOURTH QUARTER
Topics:


Related Articles
ANERGEN PUBLISHES DETAILS OF SUCCESSFUL ANIMAL STUDIES FOR MULTIPLE SCLEROSIS THERAPY
ANERGEN REPORTS THIRD QUARTER RESULTS
ANERGEN BOLSTERS SENIOR MANAGEMENT: NAMES VICE PRESIDENT, PRODUCT DEVELOPMENT AND PROMOTES VICE PRESIDENT, RESEARCH
ANERGEN REPORTS FIRST QUARTER RESULTS
ANERGEN REPORTS SECOND QUARTER RESULTS
ANERGEN REPORTS SECOND QUARTER 1996 RESULTS
Corixa Corporation to Acquire Anergen, Inc.
Corixa Corporation Completes Acquisition of Anergen Inc.
Corixa Reports Fourth Quarter and Year End Results.
Corixa Reports First Quarter Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters